Evidence Snapshot

Gamma-secretase

CHEMBL2094135 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:04:39Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 7:04 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2094135

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gamma-secretase as ChEMBL target CHEMBL2094135, mapped to UniProt Q96BI3. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Gamma-secretase

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2094135

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q96BI3

Gamma-secretase subunit APH-1A

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Gamma-secretase matters

As of 2026-09-13

Gamma-secretase is reviewed as Gamma-secretase subunit APH-1A (UniProt Q96BI3); Gamma-secretase shows approved-linked disease relevance led by Gastrointestinal desmoid tumor. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 2863 compounds, and 476 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Gamma-secretase subunit APH-1A

Gamma-secretase subunit APH-1A Sequence length is 265 aa.

Review this target as Gamma-secretase, mapped to UniProt Q96BI3. ChEMBL maps the protein component as Gamma-secretase subunit APH-1A. Sequence length is 265 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q96BI3 Protein

Disease context

Gastrointestinal desmoid tumor

Gamma-secretase shows approved-linked disease relevance led by Gastrointestinal desmoid tumor. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include NIROGACESTAT HYDROBROMIDE.

Start review with Gastrointestinal desmoid tumor because it currently carries approved-linked support. Linked drugs include NIROGACESTAT HYDROBROMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 2863 compounds, and 476 assays for this target. The dominant activity type is IC50. CHEMBL4456488 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4456488 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

1 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Gamma-secretase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96BI3, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Gastrointestinal desmoid tumor is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2863

Total Compounds

476

Total Assays

Approved Drugs

IC50: 3542.0, KI: 30.0, EC50: 160.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL4456488	11.0	EC50	—
No preferred name CHEMBL4443026	10.9	EC50	—
No preferred name CHEMBL4525398	10.9	EC50	—
No preferred name CHEMBL4547187	10.9	EC50	—
No preferred name CHEMBL4535601	10.9	EC50	—